New immunotherapy combo eyed for rare eye cancer before surgery
NCT ID NCT07501117
First seen Apr 11, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This early-stage trial tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before eye removal surgery is safe and doable for people with high-risk uveal melanoma, a rare eye cancer. About 15 participants will receive the drugs, then have their eye removed. Researchers will monitor side effects and check if the treatment shrinks the tumor or improves long-term outcomes. This is not a cure, as the eye is still removed and ongoing monitoring for spread is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
Herlev, Herlev, 2730, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.